Journal article

Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults

Yen Ying Lim, Kathryn A Ellis, Robert H Pietrzak, David Ames, David Darby, Karra Harrington, Ralph N Martins, Colin L Masters, Christopher Rowe, Greg Savage, Cassandra Szoeke, Victor L Villemagne, Paul Maruff

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012

Grants

Funding Acknowledgements

Funding for the study was provided in part by the study partners (Australian Commonwealth Scientific Industrial and Research Organization, Edith Cowan University, Mental Health Research Institute, Alzheimer's Australia, National Ageing Research Institute, Austin Health, CogState Ltd., Hollywood Private Hospital, and Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council and the Dementia Collaborative Research Centres program, as well as ongoing funding from the Science and Industry Endowment Fund.Y.-Y. Lim and K. A. Ellis report no disclosures. R. H. Pietrzak is a scientific consultant to CogState Ltd., the company that provided the CogState battery of tests used in this study. D. Ames has served on scientific advisory boards for Novartis, Eli Lilly, Janssen, and Pfizer Inc.; has received funding for travel from Janssen and Pfizer Inc.; has received speaker honoraria from Pfizer Inc. and Lundbeck Inc.; and has received research support from Eli Lilly and Company, GlaxoSmithKline, Forest Laboratories Inc., Novartis, and CSIRO. D. Darby is a scientific consultant to CogState Ltd., the company that provided the CogState battery of tests used in this study and is a shareholder of stock in CogState Ltd. K. Harrington reports no disclosures. R. N. Martins serves as consultant to the small biotech company Alzhyme; currently no financial benefits or fees accepted; research support, government entities: CSIRO flagship funding for 3 years at

million per annum; stock/stock options/board of directors compensation: holds stock for the small biotech company Alzhyme, which is not listed. C. L. Masters reports no disclosures. C. Rowe serves on scientific advisory boards for Bayer Schering Pharma, Elan Corporation, and AstraZeneca; has received speaker honoraria from Bayer Schering Pharma; and receives research support from Bayer Schering Pharma, Avid Radiopharmaceuticals, Inc., CSIRO, and the Alzheimer's Association. G. Savage reports no disclosures. C. Szoeke has previously been a clinical consultant and received speaker honoraria from Pfizer, sanofi-aventis, Mayne Pharma, and Lundbeck; has been employed as Commercial Entity Clinical Consultant, Preventive Health, CSIRO Associate Professor, Women's Healthy Ageing, National Ageing Research Institute, University of Melbourne; research support, government entities: NHMRC, chief investigator, 2009, 2010; academic entities: National Ageing Research Institute, University of Melbourne, Melbourne Health; research support, foundations, and societies: ESA, Epilepsy Fellowship, 2007 Bio21, Pharmacogenetics Overseas Training Scholarship, 2008 RACP, PostDoc Scholarship, 2007 Alzheimer's Association of Australia, Research Fellow, 2008-2010, Scobie and Claire McKinnon Foundation, chief investigator, 2009, Collier Foundations, chief investigator, 2009, and Brain Foundation, chief investigator, 2010. V. L. Villemagne serves as a consultant for Bayer Schering Pharma and receives research support from NHMRC and NEDO, Japan. P. Maruff is a full-time employee of CogState Ltd. Go to Neurology.org for full disclosures.